COVID-19 has strained the FDA to quickly evaluate new drugs and vaccines. But the tension between urgency and safety is not new—Can COVID-19 policymakers learn from the HIV epidemic? I trace the FDA’s history and offer a path toward transparency and trust: https://blog.northwesternlaw.review

Grappling with adherence, risk, and efficacy is a central problem of HIV PrEP public health policy. How have these (often contested) concepts been informed by two decades of PrEP clinical research? My new paper in Social Studies of Science: https://doi.org/10.1177/0306312720933943